Skip to main content
Oria Health
anti-inflammatorygut healthskin

KPV

Alpha-MSH C-terminal fragment · NF-kB inhibitor

A tripeptide fragment of alpha-melanocyte-stimulating hormone with potent anti-inflammatory properties via NF-kB inhibition. Studied for inflammatory bowel disease, skin conditions, and systemic inflammation without immunosuppressive effects.

KPV
Evidence Grade
C+
Trial Stage
Pre-clinical

A tripeptide fragment of alpha-melanocyte-stimulating hormone with potent anti-inflammatory properties via NF-kB inhibition. Studied for inflammatory bowel disease, skin conditions, and systemic inflammation without immunosuppressive effects.

C+
Evidence Grade
Sequence
Lys-Pro-Val
α-MSH fragment (11-13)
Mechanism
NF-κB ↓
anti-inflammatory signaling
Human Trials
0
pre-clinical only
Oral Bioavailability
Yes
PepT1 transporter
Side Effect Profile
Low
Moderate
Serious
Well-tolerated95%
Injection site reactions5%
Mild GI discomfort3%
Research Timeline
1980s
α-MSH anti-inflammatory effects
2008
KPV IBD studies (Kannengiesser)
2010s
Gut inflammation research
2020s
Peptide therapy interest
Research In Progress·Full clinical analysis pending. Community notes and FAQ available below.

KPV is a tripeptide (lysine-proline-valine) isolated from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), a peptide the body produces naturally with roles in pigmentation, appetite regulation, and immune modulation. Researchers found that this three-amino-acid sequence carries most of the parent peptide's anti-inflammatory activity — without the pigmentation changes or appetite effects of full alpha-MSH. The result is a cleaner signal: calming inflammation without triggering broader hormonal cascades.

Its primary mechanism is inhibition of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells), the transcription factor that acts as a master regulator of inflammatory gene expression. By blocking NF-kB at the source, KPV reduces inflammatory cytokine production in a fundamentally different way than NSAIDs (which block COX enzymes) or corticosteroids (which broadly suppress immune function). KPV also has direct antimicrobial properties against certain bacteria and fungi, which contributes to its benefits for both skin and gut health. Critically, it does not suppress the immune system — it modulates inflammatory signaling while preserving the body's ability to fight infection.

Research has focused on inflammatory bowel disease, skin inflammation including psoriasis and eczema, and systemic inflammation from training load. Individual variability is real: some users see dramatic improvement within days, others require several weeks, and a subset does not respond. Starting doses low (250 mcg) and titrating up is the standard approach. KPV is frequently cycled at 60 days on, 20 days off as part of the KLOW stack (KPV, BPC-157, TB-500, GHK-Cu).

LIGANDRECEPTORG-PROTEINEFFECTOR

Community Experiences

"Great for overall inflammation, skin inflammation and gut health, fungus, etc. My toenail never gets yellow anymore, dandruff completely gone, skin is calmer and my digestion can handle lactose more." — r/Biohackers

"Inflammation is noticeably down. When I train and do long runs my ankle swells. With KPV, it has not." — r/Biohackers

"Allows me to push the boat out on occasions with food and keeps my psoriasis under control. Surprisingly it also helped with my cardiac SVT — was having episodes 4 times a month, since January I've had none." — r/Biohackers

KPV research

Anti-inflammatory peptide research targeting NF-kB pathways

Frequently Asked Questions

Is KPV safe? KPV is a naturally occurring fragment of alpha-MSH, a peptide your body already produces. It has been studied in preclinical and early clinical contexts with a favorable safety profile. No serious adverse effects have been reported.

How long does KPV take to work? Results vary significantly. Some users report gut improvements within days. Skin and systemic inflammation benefits typically appear within 2 to 4 weeks. Individual variability is high.

What is the typical research dose? Doses in research communities range from 250 mcg to 1 mg daily. Most users find a sweet spot around 300 to 500 mcg. Starting low and titrating up is recommended.

Can KPV be taken orally? Subcutaneous injection is the primary method discussed in research communities. Oral bioavailability is uncertain and most researchers prefer injection for reliable absorption.

Stacking Suggestions

  • BPC-157 for a gut-focused healing stack — KPV handles anti-inflammation, BPC-157 handles tissue repair
  • TB-500 for broader tissue repair alongside KPV's inflammation control
  • GHK-Cu topically while KPV works systemically for skin conditions
  • Full KLOW stack (KPV + BPC-157 + TB-500 + GHK-Cu) for comprehensive healing protocols

Get Your BioStack →